Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab versus intravenous cyclophosphamide for connective tissue disease-associated interstitial lung disease
2012-003633-42Phase 2Unknown
- Sponsor
- Royal Brompton and Harefield hospitals
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in connective tissue disease-associated interstitial lung disease (CTD-ILD) comparing Rituximab arm with Cyclophosphamide arm (2 arms). Primary endpoint: Absolute change in forced vital capacity. Status: unknown.
02
Drugs
rituximabcyclophosphamide
03
Conditions
connective tissue disease-associated interstitial lung disease (CTD-ILD)
Beyond the preview
Go deeper on 2012-003633-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003633-42.